ACM
ESPR

Altium Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Altium Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-620,000
Closed -$3.86M – 95
2022
Q4 		$3.86M Sell
620,000
-39,869
-6% -$285K 1.96% 19
2022
Q3 		$4.42M Sell
659,869
-503,000
-43% -$3.45M 1.62% 15
2022
Q2 		$7.4M Sell
1,162,869
-1,333,655
-53% -$7.56M 2.96% 4
2022
Q1 		$11.6M Sell
2,496,524
-19,261
-0.8% -$82.6K 3.88% 2
2021
Q4 		$12.6M Buy
+2,515,785
New +$20.1M 3.47% 1

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Altium Capital Management's ESPR Position: Q1 2023 in Review

Altium Capital Management sold out of Esperion Therapeutics (ESPR) in Q1 2023, closing a stake of 620,000 shares — an estimated $3.86M sold.

Altium Capital Management first reported a position in ESPR in Q4 2021 and held it in 5 quarters. The position peaked at $12.6M in Q4 2021. 164 funds tracked by Wall St. Rank hold ESPR as of Q1 2023.

  • Altium Capital Management reported no remaining Esperion Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Altium Capital Management sold 620,000 Esperion Therapeutics shares in Q1 2023, an estimated $3.86M.
  • Altium Capital Management first reported a position in Esperion Therapeutics in Q4 2021 and held it in 5 quarters.
  • Altium Capital Management's Esperion Therapeutics position peaked at $12.6M in Q4 2021.
  • 164 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2023.

Based on Altium Capital Management's 13F filing for Q1 2023, filed 15 May 2023.